ERBB2 and breast carcinoma: The screening and selection of patients suitable for Mesothelin-targeting therapies on the basis of their Mesothelin expression in tumor biopsies is easy to perform and daily routine in other tumor entities (e.g. HER2/neu in breast cancer).